Table 1.

Demographic and clinical characteristics of patients and controls

Cancer patients (n = 249)
Melanoma (n = 80)Bladder (n = 80)Ovarian (n = 89)
Sex (M/F, %M)a43/37 (53.7%)68/12 (85%)0/89 (0%)
Age (mean ± SD)60.6 ± 15.471.8 ± 10.258.7 ± 10.7
Months from diagnosis, mean ± SD4.6 ± 14.514.9 ± 32.87.0 ± 19.6
Histology (n)b35/4536/4469/20
Staging (n)c51/292/7826/63
Treatmentd10/9/6151/20/932/49/8
Progression (yes/no, %)27/80 (33.7%)24/80 (30.0%)37/89 (41.6%)
Death (yes/no, %)7/73 (8.7%)12/80 (15.0%)20/89 (22.5%)
  • 1Control group: This genetic study included 621 healthy controls (57 ± 15 years, 50% males); 42 of them (59 ± 13.1 years, 37% males) were used for the cellular study by flow cytometry. Mean age and sex of total cancer group (n = 249) were 63.1 ± 13.5 years, 44.4% males. Controls and patients were all of Caucasian origin.

  • bFor melanoma (nodular/others), bladder (muscle invasive/superficial), ovarian (high-degree serous, undifferentiated, and carcinomas/others).

  • cFor melanoma (Breslow depth <4 mm/>4 mm), bladder cancer (grade I or II/III), and ovarian carcinoma (grade I or II/III or IV).

  • dFor melanoma (interferon-alpha/vemurafenib/others), bladder cancer (BCG/cystectomy with or without chemotherapy/no treatment), and ovarian carcinoma (surgery + chemotherapy/neoadjuvant chemotherapy + surgery/palliative).